Drug Trial Radar · NCT05040932
Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy
Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Dec 7, 2021
Primary completion
Jun 16, 2023
Study completion Jun 16, 2023
Sponsor
- Lead sponsor
- Eucure (Beijing) Biopharma Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
YH004 is a humanized monoclonal antibody that specifically binds to 4-1BB, and acts as an agonist against 4-1BB. This first in human study of YH004 is designed to establish the maximum tolerated dose (MTD) and/or the recommended Phase II dose (RP2D) of YH004, both as a single agent (monotherapy) and in combination with a fixed dose of anti-PD-1 antibody (Toripalimab) in the treatment of advanced solid tumors and relapsed or refractory non-Hodgkin Lymphoma.
Conditions
- Cancer
Interventions
YH004Drug
IV infusion once every 3 weeks (Q3W).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-emergent adverse events (TEAEs) including determination of DLTs and serious AEs (SAEs)Time frame: up to 24 months
- Maximum tolerated dose (MTD) and/or the recommended Phase II dose (RP2D)Time frame: up to 24 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Cabrini Health Limited
Malvern East, Australia
Westmead Hospital
Sydney, Australia
Southside Cancer Care Centre, School of Medicine, University of Wollongong
Wollongong, Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.